Bicycle Therapeutics plc

AI-generated fair value estimate for this company.

Method: Risk-adjusted sum-of-the-parts NPV: $495.4M net cash ($510.1M cash & equivalents less $14.7M debt, Q2 2026) plus risk-adjusted pipeline NPV of BT8009/zelenectide pevedotin (Nectin-4 ADC in metastatic urothelial cancer: $900M unrisked peak sales, 25% probability of success, 20% peak operating margin, 4x NPV multiple, discounted 5 years at 12%) and BT5528/nuzefatide pevedotin (early pancreatic program: $20M risk-adjusted NPV); 69.99M diluted shares outstanding.

Reasoning: Bicycle is a clinical-stage biotech with no meaningful recurring revenue, so a cash-flow DCF does not apply; sum-of-the-parts (net cash plus risk-adjusted pipeline NPV) is the standard method for binary-outcome biotech valuation. Net cash alone ($7.08/share) already exceeds the $3.65 share price, reflecting market skepticism after 2026 layoffs and delayed catalysts, so I gave the pipeline only partial credit despite strong 65% ORR data from the Duravelo-2 trial.